



WuXi Biologics' Ultra 96+ uHTP antibody production platform can support drug development along with automated protein production integrated with expression, purification, and analytical modules. A daily production throughput of ~1,000 antibodies is performed in 96 and 24 deep-well plates (DWP).


**96/24 well DWP for 100-1,500 µg antibodies;  
Suitable for *in vitro* assays**



- ✓ Protein with one-step purification delivered within 3 weeks
- ✓ Expression scale is 1~3 mL using 96/24 deep-well plate
- ✓ Obtain 100~1,500 µg protein sufficient for *in vitro* studies



Automated protein production platform integrated with transfection, purification, and analytical modules






- Automated expression and purification
- 3 mL culture; average yield ~0.5-1.0 mg/well
- One-step Protein A purification

**Ultra 96+ Service Details:**

Service Item	Deliverables	Duration	QC
Construct generation, cloning and plasmid prep all included.			
96 x 0.8 mL CHO/HEK293	100-800 µg	3 weeks	Titer, A280, Caliper (R/NR), and SEC-HPLC
24 x 3 mL CHO/HEK293	0.5-2 mg	3 weeks	


## The Average Titer and Recovery Rate of Ultra 96+ Platform

The left histogram shows the average titer of mAb and Fc fusion protein production using the Ultra 96+ platform. High-titer production was accomplished with both types of antibodies in the 96 DWP at 1 mL culture volume. The graphs show an average recovery rate of 83% or more was achieved in both 1 mL culture using 96 DWP and 3 mL culture using 24 DWP.



## Case Study: WuXian™ uHTP Platform

The Ultra 96+ platform incorporates an ultra-high titer transient CHO expression system that significantly enhances titers and overall yields. In this case study, the Ultra 96+ platform showcases remarkable mean final yield of antibody drug molecules in 1 mL culture using 96-DWP, achieving 1.2 mg for 960 antibodies, 0.98 mg for 536 VHH-Fc, 0.55 mg for 557 Fab, and 0.3 mg for 100 His-VHH. The proteins are suitable for *in vitro* assays.



### About WuXi Biologics

WuXi Biologics is a leading contract research, development and manufacturing organization (CRDMO) that provides end-to-end capabilities to healthcare organizations worldwide. With operations in China, the United States, Ireland, Germany, and Singapore, we enable our partners to effectively and efficiently bring biologics and vaccines to patients worldwide through our comprehensive and high-quality drug development model.

The world's leading global single-source platform from concept to commercialization.

wuxibiologics.com | info@wuxibiologics.com

**WuXi Biologics**  
Global Solution Provider

Learn more:  
Protein Sciences: uHTP Antibody  
Production

